Apoaequorin
A calcium-binding protein originally derived from the jellyfish Aequorea victoria, marketed as a memory supplement under the brand name Prevagen, though its cognitive benefits remain scientifically unsubstantiated.
Overview
Apoaequorin is a calcium-binding protein originally isolated from the bioluminescent jellyfish Aequorea victoria. The protein contains three EF-hand motifs that serve as binding sites for calcium ions, placing it within the superfamily of EF-hand calcium-binding proteins. Although originally extracted from jellyfish, commercial apoaequorin is now produced recombinantly in Escherichia coli. It is the active ingredient in Prevagen, a dietary supplement marketed by Quincy Bioscience for memory support, available in doses of 10, 20, and 40 mg.
The proposed mechanism behind apoaequorin's claimed cognitive benefits centers on calcium regulation in the brain, as intracellular calcium homeostasis is important for neuronal function and signaling. However, significant scientific concerns undermine this hypothesis. As a protein, apoaequorin is likely digested into amino acids in the gastrointestinal tract before it could reach the brain intact, making its proposed mechanism biologically implausible according to multiple expert analyses. The primary clinical study cited by the manufacturer — the Madison Memory Study involving 218 adults — did not demonstrate statistically significant cognitive improvements on its primary endpoints, with only selective post hoc analyses yielding positive results.
In 2017, the U.S. Federal Trade Commission charged Quincy Bioscience with false advertising, alleging that claims of memory improvement were not supported by competent scientific evidence. The FTC prevailed in its case in 2024, and the company is now prohibited from making unsubstantiated cognitive benefit claims. While apoaequorin appears to be generally well-tolerated at standard doses, reported adverse effects include headache, dizziness, and nausea. The scientific consensus holds that there is no reliable evidence supporting apoaequorin as an effective cognitive supplement.
Mechanism of Action
Calcium-Binding Protein Structure
Apoaequorin is a 22-kDa calcium-binding protein originally isolated from the bioluminescent jellyfish Aequorea victoria. It contains three EF-hand calcium-binding domains — helix-loop-helix motifs that bind Ca²⁺ ions with high affinity. In its native context, apoaequorin combines with the chromophore coelenterazine and molecular oxygen to form the photoprotein aequorin, which emits light upon calcium binding (PMID: 3120188).
Proposed Neuroprotective Mechanism
The hypothesized mechanism for apoaequorin's cognitive effects centers on intracellular calcium buffering in neurons. Age-related calcium dysregulation (the "calcium hypothesis of aging") involves excessive cytoplasmic Ca²⁺ accumulation from overactive NMDA receptors, L-type voltage-gated calcium channels, and impaired mitochondrial/ER calcium sequestration. Apoaequorin's EF-hand domains theoretically sequester excess intracellular calcium, protecting neurons from calcium-mediated excitotoxicity and apoptotic cascading (PMID: 21060172).
Calcium Homeostasis & Neuronal Survival
Calcium overload activates destructive cascades including calpain protease activation (degrading cytoskeletal and synaptic proteins), mitochondrial permeability transition pore opening (releasing cytochrome c), and calcineurin-mediated dephosphorylation of pro-survival factors. By buffering excess Ca²⁺, calcium-binding proteins help maintain the narrow concentration window (50-100 nM resting) essential for normal synaptic transmission and plasticity (PMID: 19549037).
Bioavailability Considerations
A significant question in apoaequorin's mechanism is oral bioavailability of an intact protein. As a 189-amino-acid polypeptide, it is expected to undergo proteolytic degradation in the GI tract. The manufacturer (Quincy Bioscience) has published one controlled trial (the Madison Memory Study) suggesting modest improvements in cognitive function, but the mechanism by which an orally ingested protein survives digestion to reach the CNS remains scientifically debated (PMID: 26878879).
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Reported Effects
Limited Clinical Evidence:: Only one published human trial with modest results; most evidence comes from animal and in vitro studies. Questionable Bioavailability:: As a protein supplement, unclear if apoaequorin survives digestion and crosses the blood-brain barrier effectively. Regulatory Scrutiny:: Has faced FTC complaints regarding advertising claims about memory improvement benefits. Research-Practice Gap:: Scientific plausibility exists but clinical translation remains poorly demonstrated
- Only one published human trial with modest results; most evidence comes from animal and in vitro studies
- As a protein supplement, unclear if apoaequorin survives digestion and crosses the blood-brain barrier effectively
- Has faced FTC complaints regarding advertising claims about memory improvement benefits
- Scientific plausibility exists but clinical translation remains poorly demonstrated
Safety Profile
Common Side Effects
- Headache is the most frequently self-reported side effect, though clinical trials have not consistently differentiated this from placebo rates.
- Mild gastrointestinal discomfort including nausea and bloating reported by a small percentage of users.
- Dizziness and lightheadedness have been occasionally noted.
- Insomnia or sleep disturbances when taken in the evening, though evidence is largely anecdotal.
Contraindications
- Known hypersensitivity to apoaequorin or jellyfish-derived proteins. Individuals with shellfish or marine organism allergies should exercise caution, though apoaequorin is derived from Aequorea victoria (crystal jellyfish), which is taxonomically distinct from shellfish.
- Severe calcium metabolism disorders: Apoaequorin is a calcium-binding protein; theoretical concerns exist regarding interference with calcium homeostasis, though clinical significance has not been established.
- The FDA issued a warning letter to the primary manufacturer (Quincy Bioscience) regarding unsupported cognitive health claims, which should be considered when evaluating risk-benefit.
Drug Interactions
- Calcium channel blockers (amlodipine, diltiazem, verapamil): Theoretical interaction due to apoaequorin's calcium-binding properties, though no clinical cases have been documented. Monitor blood pressure if co-administering.
- Calcium supplements: Potential competitive binding may theoretically reduce efficacy of either compound, though this has not been demonstrated clinically.
- No significant cytochrome P450 interactions have been identified in available studies.
- Minimal protein binding suggests low risk of displacement interactions with highly protein-bound drugs.
Special Populations
- Pregnancy and lactation: No safety data available; use is not recommended.
- Pediatric use: Not studied in children; not recommended for individuals under 18.
- Elderly: The primary target demographic. The Madison Memory Study (a manufacturer-sponsored trial) showed tolerability in adults over 40, but independent replication is limited.
- Renal or hepatic impairment: No specific studies; the protein is expected to be metabolized via normal proteolytic pathways, but caution is advised.
Monitoring
- Cognitive function assessments if using for memory support (to evaluate efficacy rather than safety).
- Serum calcium levels if used concurrently with calcium-modulating medications.
- General adverse event reporting, as post-market surveillance data is still limited.
- No routine laboratory monitoring is currently recommended for otherwise healthy adults.
Pharmacokinetic Profile
Apoaequorin — Pharmacokinetic Curve
SubcutaneousQuick Start
- Typical Dose
- Typically marketed at 10mg per day as found in Prevagen products
Safety Profile
Common Side Effects
- Minimal Reported Toxicity:: No clinically apparent liver injury or serious adverse effects documented in safety studies
- Digestive Tolerance:: As a protein supplement, generally well-tolerated with few gastrointestinal complaints
- Lack of Long-term Data:: Limited information on effects of extended use beyond 90-day study periods
- Individual Variation:: Like other supplements, response may vary based on individual calcium metabolism and protein digestion
References (6)
- [5]Computational comparison of a calcium-dependent jellyfish protein (apoaequorin) and calmodulin-cholesterol in short-term memory maintenance
→ Computational analysis revealed that apoaequorin contains three calcium-binding sites and four cholesterol-binding domains, with structural similarities to calmodulin that may support its role in memory reconsolidation through calcium-dependent kinase regulation.
- [1]Effects of a Supplement Containing Apoaequorin on Verbal Learning in Older Adults in the Community
→ A randomized, double-blind, placebo-controlled trial of 218 adults aged 40-91 with memory concerns found that 90 days of apoaequorin supplementation showed some improvements in verbal learning and working memory using computerized cognitive assessments.
- [2]Pretreatment with apoaequorin protects hippocampal CA1 neurons from oxygen-glucose deprivation
→ In vitro rat brain slice studies demonstrated that intra-hippocampal infusion of apoaequorin dose-dependently protected neurons from ischemic cell death following oxygen-glucose deprivation, suggesting neuroprotective properties through calcium regulation.
- [3]Apoaequorin differentially modulates fear memory in adult and aged rats
→ Research in rats showed that apoaequorin can modulate fear memory processing differently in adult versus aged animals, supporting the hypothesis that calcium-binding protein administration may influence cognitive function during aging.
- [4]Safety assessment of Apoaequorin, a protein preparation: subchronic toxicity study in rats
→ A 90-day toxicity study in rats found no adverse effects from apoaequorin at doses up to 666.7 mg/kg body weight per day, establishing a No Observed Adverse Effect Level (NOAEL) and supporting its safety profile as a dietary supplement.
- [6]Over the Counter Supplements for Memory: A Review of Available Evidence
→ A comprehensive 2023 review of memory supplements found limited robust evidence for most over-the-counter products, highlighting the lack of FDA oversight and the need for critical evaluation of supplement claims including those for apoaequorin.
Apigenin
Apigenin is a naturally occurring flavonoid compound found abundantly in chamomile, parsley, celery, and other fruits and vegetables. It works through multiple
Ara 290
**ARA-290** (cibinetide) is a synthetic 11-amino acid peptide engineered from the three-dimensional structure of the tissue-protective domain of erythropoietin